

SYN-ONE TEST® REQUISITION FORM

□ Syn-One Test[®] for Synucleinopathy

Syn-One is an anatomical pathology test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers to support a diagnosis of a synucleinopathy: Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), pure autonomic failure (PAF), or REM sleep behavior disorder (RBD). Syn-One also measures the density of intraepidermal nerve fibers to support a diagnosis of small fiber neuropathy. For other important insights, Syn-One includes modified Congo Red staining to identify amyloid proteins to support a diagnosis of amyloidosis and hematoxylin and eosin for skin morphology.

Individual Test Options 🗌 Synuclein + Skin histology (H&E) 🗋 Synuclein + IENFD (PGP 9.5) + Skin histology (H&E) 🗌 Amyloidosis (Congo Red) + Skin histology (H&E)

PLEASE INCLUDE ALL INFORMATION BELOW TO AVOID PROCESSING DELAYS. INCLUDE PRINTED COPIES OF REQUESTED INFORMATION WITH SPECIMEN SHIPMENT.					
Primary insurance card (front/back)	Government issued ID (front/back)	Patient demographic information (face sheet, etc.)			

Secondary insurance card (front/back)

Relevant medical records

Assignment of benefits

CPT codes for standard Syn-One Test panel: 88305 x 3, 88314 x 3, 88346 x 2, 88350 x 4, 88356 x 3 Codes and units reflect standard biopsy sites and number of biopsies. Codes and units may vary if non-standard number of biopsies are used.

PATIENT INFORMATION

First Name		Middle Initial	Last Name / Surname		
Phone Number	Date of Birth (Month/Day/Year)	Sex at I	Birth	ICD-10 Codes	
			ile male · Identity:	G60.3 Idiop G20 Parkin Other:	athic Neuropathy sonism
Street Address		City			State
ZIP or Postal Code		Email Address			
Primary Insurance Name/Member ID	Secondary Insurar	nce Name/Membe	er ID	Other Insurance Name/	Member ID

PRACTICE INFORMATION

State
(International Only)
ldress

PLEASE COMPLETE AND SIGN THE OTHER SIDE OF THIS DOCUMENT MISSING INFORMATION MAY CAUSE DELAYS.

SYNUCLEINOPATHY CLINICAL INFORMATION

Family History of Parkinson's Disease	Yes	No No	Unknown
Response to L-Dopa	Yes	No No	Unknown
Response to Dopaminergic Agonists	Yes	No No	Unknown
Dementia	Yes	No No	Unknown
Irregular Autonomic Function	Yes	No No	Unknown
Resting Tremors	Yes	No No	Unknown
Orthostatic Hypotension	Yes	No No	Unknown

REM Sleep Behavioral Disorder	Yes	No No	Unknow
Loss of Smell (Anosmia)	Yes	No No	Unknow
Periods of Confusion/Hallucinations	Yes	No	Unknowi
Constipation	Yes	No	Unknow
Bladder Dysfunction	Yes	No	Unknow
DaTScan Result	Normal	Abnormal	Unknow

3MM SKIN BIOPSY SPECIMEN INFORMATION

Posterior Cervical - 3 cm laterally from C7 vertebrae	• When per punch to rotation
• Distal Thigh - 10 cm above lateral knee	Make su
Distal Leg - 10 cm above lateral malleolus	

es:

- erforming the biopsy, the metal head of the ool should be used with gentle pressure and until fully into the skin
- nandle the biopsy with the forceps
- are the biopsy is free floating in the vial

Clinician Performing Biopsy		Physician NPI (US) or Clinician ID Nu	mber (International)		
Date of Specimen (Mont	th/Day/Year)		Time of Specimen			AM
Biopsy Sites	Side (Choose One)	Location (Choose One)				
Specimen 1	Right Left	Posterior Cervical	Distal Thigh	Distal Leg	Other:	
Specimen 2	Right Left	Posterior Cervical	Distal Thigh	Distal Leg	Other:	
Specimen 3	Right Left	Posterior Cervical	Distal Thigh	Distal Leg	Other:	

The undersigned certifies that he/she is licensed to order the test(s) selected and that such test(s) are medically necessary for the care/treatment of this patient.

Authorized Signature				Date
For Internal Use Only				
Case #	Date Received	# of Biopsies	Biopsy Locations	Initials
CND Life Sciences 9165 E D	Del Camino Dr., Suite 101 Scottsdale, AZ	85258-4381 cndlifescience	es.com Phone: 480.569.2900 Fax:	480.569.2910 CLIA# 03D2151444

Immunofluorescent tests were developed, and their performance characteristics were determined by CND Life Sciences, Scottsdale, AZ. These tests have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. These tests should not be regarded as investigational or for research. CND is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing. All histochemical and immunofluorescent controls are in accordance with quality assurance standards.